Experienced in Thrombocytopenia

Dr. James E. Liebmann

Oncology | Hematology Oncology | Hematology
Northeast Medical Practice Inc
85 Herrick St, 
Beverly, MA 
Accepting New Patients
Offers Telehealth
Experienced in Thrombocytopenia
Northeast Medical Practice Inc
85 Herrick St, 
Beverly, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

James Liebmann is an Oncologist and a Hematologist Oncology provider in Beverly, Massachusetts. Dr. Liebmann is rated as an Experienced provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Inflammatory Breast Cancer, Paget Disease of the Breast, Lung Cancer, and Small Cell Lung Cancer (SCLC). Dr. Liebmann is currently accepting new patients.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Hematology
Licenses
Internal Medicine in MA
Hospital Affiliations
Winchester Hospital
Lahey Hospital & Medical Center, Burlington
Northeast Hospital Corporation
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

NORTHEAST MEDICAL PRACTICE INC
85 Herrick St, Beverly, MA 01915
Other Locations
NORTHEAST MEDICAL PRACTICE INC
298 Washington St, Gloucester, MA 01930
NORTHEAST MEDICAL PRACTICE INC
41 Mall Rd, Burlington, MA 01805

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
View 5 Less Clinical Trials

4 Total Publications

Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience.
Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience.
Journal: Journal for immunotherapy of cancer
Published: February 13, 2018
Similar Doctors
Elite in Thrombocytopenia
Dr. David J. Kuter
Hematology | Oncology
Elite in Thrombocytopenia
Dr. David J. Kuter
Hematology | Oncology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (17.1 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Kuter is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Kuter is rated as an Elite provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, Thrombocytopenia, Autoimmune Hemolytic Anemia, and Splenectomy. Dr. Kuter is currently accepting new patients.

Distinguished in Thrombocytopenia
Dr. Pavan K. Bendapudi
Hematology Oncology | Hematology
Distinguished in Thrombocytopenia
Dr. Pavan K. Bendapudi
Hematology Oncology | Hematology

Massachusetts General Physicians Organization Inc

75 Francis St, 
Boston, MA 
 (19.7 miles away)
617-732-5500
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Pavan Bendapudi is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Bendapudi is rated as a Distinguished provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Purpura, Thrombocytopenia, Blood Clots, and Disseminated Intravascular Coagulation. Dr. Bendapudi is currently accepting new patients.

Elite in Thrombocytopenia
Dr. Camille L. Bedrosian
Hematology Oncology
Elite in Thrombocytopenia
Dr. Camille L. Bedrosian
Hematology Oncology
26 Landsdowne Street, 
Cambridge, MA 
 (18.1 miles away)
617-494-0400
Languages Spoken:
English
See accepted insurances

Camille Bedrosian is a Hematologist Oncology provider in Cambridge, Massachusetts. Dr. Bedrosian is rated as an Elite provider by MediFind in the treatment of Thrombocytopenia. Her top areas of expertise are Hemolytic-Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, D-Minus Hemolytic Uremic Syndrome, and Atypical Hemolytic Uremic Syndrome (aHUS).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Liebmann's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 26 Advanced Conditions
    View All 104 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile